MABVAX THERAPEUTICS HLDGS IN's ticker is MBVXQ and the CUSIP is 55414P702. A total of 15 filers reported holding MABVAX THERAPEUTICS HLDGS IN in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 8,903 | $8,000 | 0.12% |
| Cambridge Investment Research Advisors, Inc. | 1,030,310 | $876,000 | 0.01% |
| ROYAL BANK OF CANADA | 2,999 | $3,000 | 0.00% |
| VANGUARD GROUP INC | 126,592 | $108,000 | 0.00% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 2 | $0 | 0.00% |
| UBS Group AG | 11,889 | $10,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 6,664 | $6,000 | 0.00% |
| DEUTSCHE BANK AG\ | 1 | $0 | 0.00% |
| Brinker Capital Investments, LLC | 333 | $0 | 0.00% |
| Financial Architects, Inc | 2 | $0 | 0.00% |